{"id":"NCT03001011","sponsor":"Sanofi","briefTitle":"Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China","officialTitle":"A Randomized, Double Blind, Parallel Group Study For Assessing The Efficacy And Safety Of RenvelaÂ® Tablets For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease Not On Dialysis Versus Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-07","primaryCompletion":"2019-08-16","completion":"2019-08-16","firstPosted":"2016-12-22","resultsPosted":"2020-07-28","lastUpdate":"2022-03-25"},"enrollment":202,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperphosphatemia"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Sevelamer Carbonate (GZ419831)","otherNames":["Renvela"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Renvela","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate efficacy of Renvela tablets in the reduction of serum phosphorus in hyperphosphatemia in participants with chronic kidney disease not on dialysis.\n\nSecondary Objectives:\n\nTo document the efficacy of Renvela tablets in the reduction of serum lipids (total cholesterol and low-density lipoprotein cholesterol \\[LDL-C\\]).\n\nTo document the efficacy of Renvela tablets in the reduction of calcium-phosphorus product.\n\nTo document the efficacy of Renvela tablets in the reduction of intact parathyroid hormone (iPTH).\n\nTo document the efficacy of Renvela tablets in proportion of participants reaching the target serum phosphorus level 4.6 milligrams per decilitre (mg/dL) (1.47 millimoles per litre \\[mmol/L\\], inclusive).\n\nTo evaluate safety of Renvela tablets.","primaryOutcome":{"measure":"Change From Baseline in Serum Phosphorus at Week 8","timeFrame":"Baseline, Week 8","effectByArm":[{"arm":"Placebo","deltaMin":2.09,"sd":null},{"arm":"Renvela","deltaMin":2.095,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":38,"countries":["China"]},"refs":{"pmids":["40576086"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":101},"commonTop":["Hyperkalaemia","Nausea","Vomiting","Oedema Peripheral","Upper Respiratory Tract Infection"]}}